 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Imitrex, Imigran, others |
| AHFS/ Drugs.com | Monograph |
| License data |
|
|
Pregnancy category |
|
|
Routes of administration | By mouth, subcutaneous injection, nasal spray, transdermal electrophoresis |
| Drug class | Triptan [1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 15% (by mouth) / 96% (sc) |
| Protein binding | 14–21% |
| Metabolism | MAO |
| Elimination half-life | 2.5 hours |
| Excretion | 60% urine; 40% feces |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C14H21N3O2S |
| Molar mass | 295.40 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
| (verify) | |
Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. [2] It is taken by mouth, in the nose, or by injection under the skin. [1] Effects generally occur within three hours. [1]
Common side effects include chest pressure, feeling tired, feeling of the world spinning, vomiting, and tingling. [1] Serious side effects may include serotonin syndrome, heart attacks, strokes, and seizures. [1] With excessive use medication overuse headaches may occur. [1] It is unclear if use in pregnancy or breastfeeding is safe. [4] How it works is not entirely clear. [1] It is in the triptan class of medications. [1]
Sumatriptan was patented in 1982 and approved for medical use in 1991. [5] It is available as a generic medication. [2] It is on the World Health Organization's List of Essential Medicines. [6] In the United Kingdom it costs the NHS about £1 per dose as of 2019. [2] In the United States the wholesale cost of this amount is about US$0.60. [7] In 2017, it was the 97th most commonly prescribed medication in the United States, with more than eight million prescriptions. [8] [9] It is also available as the combination product sumatriptan/naproxen at a cost of US$50 per dose. [7]
References
- ^ a b c d e f g h i "Sumatriptan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 7 March 2019. Retrieved 3 March 2019.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 474. ISBN 9780857113382.
- ^ a b c d "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 22 January 2021. Retrieved 6 September 2020.
- ^ "Sumatriptan Use During Pregnancy". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495. Archived from the original on 6 March 2019. Retrieved 2 March 2019.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ a b "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Sumatriptan - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
|
| |
|
| |
| Clinical data | |
|---|---|
| Trade names | Imitrex, Imigran, others |
| AHFS/ Drugs.com | Monograph |
| License data |
|
|
Pregnancy category |
|
|
Routes of administration | By mouth, subcutaneous injection, nasal spray, transdermal electrophoresis |
| Drug class | Triptan [1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 15% (by mouth) / 96% (sc) |
| Protein binding | 14–21% |
| Metabolism | MAO |
| Elimination half-life | 2.5 hours |
| Excretion | 60% urine; 40% feces |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C14H21N3O2S |
| Molar mass | 295.40 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
| (verify) | |
Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. [2] It is taken by mouth, in the nose, or by injection under the skin. [1] Effects generally occur within three hours. [1]
Common side effects include chest pressure, feeling tired, feeling of the world spinning, vomiting, and tingling. [1] Serious side effects may include serotonin syndrome, heart attacks, strokes, and seizures. [1] With excessive use medication overuse headaches may occur. [1] It is unclear if use in pregnancy or breastfeeding is safe. [4] How it works is not entirely clear. [1] It is in the triptan class of medications. [1]
Sumatriptan was patented in 1982 and approved for medical use in 1991. [5] It is available as a generic medication. [2] It is on the World Health Organization's List of Essential Medicines. [6] In the United Kingdom it costs the NHS about £1 per dose as of 2019. [2] In the United States the wholesale cost of this amount is about US$0.60. [7] In 2017, it was the 97th most commonly prescribed medication in the United States, with more than eight million prescriptions. [8] [9] It is also available as the combination product sumatriptan/naproxen at a cost of US$50 per dose. [7]
References
- ^ a b c d e f g h i "Sumatriptan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 7 March 2019. Retrieved 3 March 2019.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 474. ISBN 9780857113382.
- ^ a b c d "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 22 January 2021. Retrieved 6 September 2020.
- ^ "Sumatriptan Use During Pregnancy". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495. Archived from the original on 6 March 2019. Retrieved 2 March 2019.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ a b "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Sumatriptan - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.